PF icon
Feature Partner

Bright Minds

Quick Overview of Bright Minds

Company Status
Public
Private
Non-Profit
Parent Company
CSE Ticker
DRUG
FSE TICKER
OTC Ticker
TSX TICKER
TSX Venture TICKER
NEO TICKER
NASDAQ TICKER
DRUG
NYSE TICKER

Company Summary

About

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.